- Healthcare Professionals
- Latest research
- Clinical trials
- Natera 20-041-NCP
Natera 20-041-NCP
BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
Trial overview
Topic
Natera 20-041-NCP |
Description
The BESPOKE CRC study will prospectively enroll patients who have undergone surgery for stage II or III colorectal cancer (CRC) and who have residual formalin-fixed paraffin-embedded (FFPE) tissue available will provide FFPE and whole blood samples. Patients will receive SIGNATERA™ test results and may be recommended for adjuvant chemotherapy or observation by their treating clinician. Patients will be followed for up to two years with periodic whole blood collection. The study also has a control arm that will consist of matched Stage II or Stage III CRC cases that have a minimum of least 2 years clinical follow-up data. |
Physicians
Contact
East Coast-Jacksonville
Maddie Hamilton